{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:40:17Z","timestamp":1793166017383,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"16","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"crossref","award":["G-002160"],"award-info":[{"award-number":["G-002160"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["HFHF_016"],"award-info":[{"award-number":["HFHF_016"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["200937"],"award-info":[{"award-number":["200937"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2025,2,11]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus (T2D) is critical, yet evidence of adherence to guideline-recommended standards in routine care remains unclear. We aimed to assess primary care adherence to guideline-recommended standards for patients with overlapping HF, CKD and T2D in England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using UK Clinical Practice Research Datalink (1998\u20132020), we evaluated care adherence across 161\u2009529 individuals with HF, CKD or T2D before and after developing a second of these conditions. We analysed disease investigation rates, medication use and predictors of guideline adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 161\u2009529 patients with CKD followed by HF (CKD+HF, 40%), CKD+T2D (51.3%) and HF+T2D (8.6%) with a median of 3.1 years follow-up after the second diagnosis. In CKD+HF, CKD+T2D and HF+T2D groups, prescription rates of renin-angiotensin system inhibitors (71%, 64.1% and 74.4%), beta-blockers (53.1%,36.2% and 55.1%), antiplatelets (56.2%, 45.2% and 54.4%) and statins (56.7%, 68.5% and 72%) were suboptimal. Advanced age, female sex, peripheral arterial disease and cancer were associated with a lower likelihood of checking blood pressure, creatinine and glycated haemoglobin (HbA1C) after HF, CKD and T2D diagnoses, respectively. The first diagnosis of HF was associated with reduced odds of having HbA1C measured after T2D diagnosis (OR 0.79, 95% CI 0.72 to 0.86), compared with CKD as the first diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In overlapping HF, CKD and T2D, guideline-recommended care is suboptimal, with inequalities by age, sex, disease on first presentation and comorbidities. Quality improvement requires linked data collection, monitoring and action across diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/heartjnl-2024-325046","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T13:20:55Z","timestamp":1741094455000},"page":"776-785","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Missed opportunities to manage complex comorbidity of heart failure, type 2 diabetes mellitus and chronic kidney disease: a retrospective cohort study"],"prefix":"10.1136","volume":"111","author":[{"given":"Laura","family":"Pasea","sequence":"first","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Mohamed","sequence":"additional","affiliation":[{"name":"University College London, London, UK"},{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Dashtban","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-7815","authenticated-orcid":false,"given":"Anish","family":"Bhuva","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Barts Heart Centre, London, UK"},{"name":"Institute of Cardiovascular Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad A","family":"Mizani","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ali","sequence":"additional","affiliation":[{"name":"Royal Free Hospitals NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oates","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-8890","authenticated-orcid":false,"given":"Mamas A","family":"Mamas","sequence":"additional","affiliation":[{"name":"Manchester University, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamsin","family":"Morris","sequence":"additional","affiliation":[{"name":"AstraZeneca, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Gao","sequence":"additional","affiliation":[{"name":"AstraZeneca, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jil Billy","family":"Mamza","sequence":"additional","affiliation":[{"name":"AstraZeneca, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-3411","authenticated-orcid":false,"given":"Amitava","family":"Banerjee","sequence":"additional","affiliation":[{"name":"University College London, London, UK"},{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2025121416150580000_111.16.776.1","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2023-002332","article-title":"Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record study","volume":"10","author":"Pasea","year":"2023","journal-title":"Open Heart"},{"key":"2025121416150580000_111.16.776.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02234-2"},{"key":"2025121416150580000_111.16.776.3","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5688-y"},{"key":"2025121416150580000_111.16.776.4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14698"},{"key":"2025121416150580000_111.16.776.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"2025121416150580000_111.16.776.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2025121416150580000_111.16.776.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz828"},{"key":"2025121416150580000_111.16.776.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.026"},{"key":"2025121416150580000_111.16.776.9","doi-asserted-by":"publisher","DOI":"10.5334\/gh.835"},{"key":"2025121416150580000_111.16.776.10","doi-asserted-by":"publisher","DOI":"10.1177\/17423953050010010801"},{"key":"2025121416150580000_111.16.776.11","doi-asserted-by":"publisher","DOI":"10.1177\/1742395314532142"},{"key":"2025121416150580000_111.16.776.12","doi-asserted-by":"crossref","first-page":"100739","DOI":"10.1016\/j.eclinm.2021.100739","article-title":"Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years","volume":"32","author":"Lawson","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025121416150580000_111.16.776.13","doi-asserted-by":"crossref","unstructured":"Patel PA , Liang L , Khazanie P , et al . Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. Circ Heart Fail 2016;9. doi:10.1161\/CIRCHEARTFAILURE.115.002638","DOI":"10.1161\/CIRCHEARTFAILURE.115.002638"},{"key":"2025121416150580000_111.16.776.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.306924"},{"key":"2025121416150580000_111.16.776.15","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"2025121416150580000_111.16.776.16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003316","article-title":"Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease: A Clinical Conundrum","volume":"9","author":"Aguilar","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2025121416150580000_111.16.776.17","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025121416150580000_111.16.776.18","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocz105"},{"key":"2025121416150580000_111.16.776.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109036"},{"key":"2025121416150580000_111.16.776.20","doi-asserted-by":"publisher","DOI":"10.1159\/000520909"},{"key":"2025121416150580000_111.16.776.21","unstructured":"National Institute for Health and Care Excellence (NICE) . Chronic kidney disease in adults CG182 [internet]. 2014. Available: https:\/\/www.nice.org.uk\/guidance\/cg182\/"},{"key":"2025121416150580000_111.16.776.22","unstructured":"National Institute for Health and Care Excellence (NICE) . Type 2 diabetes in adults ng28 [internet]. 2015 Available: https:\/\/www.nice.org.uk\/guidance\/ng28"},{"key":"2025121416150580000_111.16.776.23","unstructured":"National Institute for Health and Care Excellence (NICE) . Chronic heart failure in adults ng106 [internet]. 2018. Available: https:\/\/www.nice.org.uk\/guidance\/ng106"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2024-325046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:15:26Z","timestamp":1765757726000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2024-325046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":23,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/heartjnl-2024-325046"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2024-325046","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}